Astera Labs, Inc. $ALAB Shares Purchased by Swiss National Bank

Swiss National Bank raised its stake in Astera Labs, Inc. (NASDAQ:ALAB) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 257,600 shares of the company’s stock after acquiring an additional 9,800 shares during the period. Swiss National Bank’s holdings in Astera Labs were worth $50,438,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Assetmark Inc. increased its position in shares of Astera Labs by 374.1% during the third quarter. Assetmark Inc. now owns 128 shares of the company’s stock worth $25,000 after purchasing an additional 101 shares in the last quarter. Clearstead Trust LLC lifted its holdings in shares of Astera Labs by 46,100.0% in the 2nd quarter. Clearstead Trust LLC now owns 462 shares of the company’s stock valued at $42,000 after purchasing an additional 461 shares during the last quarter. Advisors Asset Management Inc. boosted its position in shares of Astera Labs by 68.6% in the 2nd quarter. Advisors Asset Management Inc. now owns 477 shares of the company’s stock valued at $43,000 after purchasing an additional 194 shares during the period. Manchester Capital Management LLC grew its stake in Astera Labs by 141.5% during the 2nd quarter. Manchester Capital Management LLC now owns 483 shares of the company’s stock worth $44,000 after buying an additional 283 shares during the last quarter. Finally, Pinpoint Asset Management Singapore Pte. Ltd. purchased a new position in Astera Labs during the 3rd quarter worth approximately $47,000. Hedge funds and other institutional investors own 60.47% of the company’s stock.

Astera Labs Stock Down 3.9%

Shares of Astera Labs stock opened at $119.90 on Friday. The firm has a market cap of $20.41 billion, a price-to-earnings ratio of 98.28, a price-to-earnings-growth ratio of 2.45 and a beta of 1.74. Astera Labs, Inc. has a 52-week low of $47.13 and a 52-week high of $262.90. The company’s 50-day simple moving average is $149.08 and its 200-day simple moving average is $168.55.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings data on Tuesday, February 10th. The company reported $0.58 EPS for the quarter, beating analysts’ consensus estimates of $0.51 by $0.07. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The firm had revenue of $270.58 million during the quarter, compared to the consensus estimate of $249.46 million. During the same quarter last year, the firm earned $0.37 earnings per share. The firm’s revenue was up 91.8% compared to the same quarter last year. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. Equities research analysts anticipate that Astera Labs, Inc. will post 0.34 EPS for the current year.

Insider Buying and Selling at Astera Labs

In other news, General Counsel Philip Mazzara sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $117.47, for a total value of $1,174,700.00. Following the completion of the sale, the general counsel directly owned 128,084 shares of the company’s stock, valued at $15,046,027.48. This trade represents a 7.24% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael Truett Tate sold 12,001 shares of Astera Labs stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $123.81, for a total value of $1,485,843.81. Following the completion of the sale, the chief financial officer owned 192,083 shares in the company, valued at approximately $23,781,796.23. This trade represents a 5.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 224,292 shares of company stock worth $27,676,069. 12.50% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ALAB has been the topic of several research analyst reports. Citigroup reduced their price objective on Astera Labs from $275.00 to $250.00 and set a “buy” rating for the company in a research note on Wednesday, February 11th. Loop Capital assumed coverage on shares of Astera Labs in a research report on Thursday, March 5th. They set a “buy” rating and a $250.00 target price on the stock. Raymond James Financial started coverage on shares of Astera Labs in a report on Friday, November 21st. They issued a “hold” rating on the stock. Royal Bank Of Canada initiated coverage on shares of Astera Labs in a research report on Wednesday, January 14th. They issued an “outperform” rating and a $225.00 price target for the company. Finally, Weiss Ratings cut shares of Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 23rd. Fifteen equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $195.89.

About Astera Labs

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.